217 related articles for article (PubMed ID: 21833769)
1. Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice.
Peters V; Schmitt CP; Zschocke J; Gross ML; Brismar K; Forsberg E
Amino Acids; 2012 Jun; 42(6):2411-6. PubMed ID: 21833769
[TBL] [Abstract][Full Text] [Related]
2. Carnosine metabolism in diabetes is altered by reactive metabolites.
Peters V; Lanthaler B; Amberger A; Fleming T; Forsberg E; Hecker M; Wagner AH; Yue WW; Hoffmann GF; Nawroth P; Zschocke J; Schmitt CP
Amino Acids; 2015 Nov; 47(11):2367-76. PubMed ID: 26081982
[TBL] [Abstract][Full Text] [Related]
3. A Global Cndp1-Knock-Out Selectively Increases Renal Carnosine and Anserine Concentrations in an Age- and Gender-Specific Manner in Mice.
Weigand T; Colbatzky F; Pfeffer T; Garbade SF; Klingbeil K; Colbatzky F; Becker M; Zemva J; Bulkescher R; Schürfeld R; Thiel C; Volk N; Reuss D; Hoffmann GF; Freichel M; Hecker M; Poth T; Fleming T; Poschet G; Schmitt CP; Peters V
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664451
[TBL] [Abstract][Full Text] [Related]
4. Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity.
Peters V; Kebbewar M; Jansen EW; Jakobs C; Riedl E; Koeppel H; Frey D; Adelmann K; Klingbeil K; Mack M; Hoffmann GF; Janssen B; Zschocke J; Yard BA
Amino Acids; 2010 May; 38(5):1607-15. PubMed ID: 19915793
[TBL] [Abstract][Full Text] [Related]
5. Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration.
Peters V; Jansen EE; Jakobs C; Riedl E; Janssen B; Yard BA; Wedel J; Hoffmann GF; Zschocke J; Gotthardt D; Fischer C; Köppel H
Clin Chim Acta; 2011 Jan; 412(3-4):263-7. PubMed ID: 20971102
[TBL] [Abstract][Full Text] [Related]
6. Carnosine treatment in combination with ACE inhibition in diabetic rats.
Peters V; Riedl E; Braunagel M; Höger S; Hauske S; Pfister F; Zschocke J; Lanthaler B; Benck U; Hammes HP; Krämer BK; Schmitt CP; Yard BA; Köppel H
Regul Pept; 2014 Nov; 194-195():36-40. PubMed ID: 25234296
[TBL] [Abstract][Full Text] [Related]
7. L-carnosine, a substrate of carnosinase-1, influences glucose metabolism.
Sauerhöfer S; Yuan G; Braun GS; Deinzer M; Neumaier M; Gretz N; Floege J; Kriz W; van der Woude F; Moeller MJ
Diabetes; 2007 Oct; 56(10):2425-32. PubMed ID: 17601992
[TBL] [Abstract][Full Text] [Related]
8. Human carnosinase 1 overexpression aggravates diabetes and renal impairment in BTBR
Qiu J; Albrecht T; Zhang S; Hauske SJ; Rodriguez-Niño A; Zhang X; Nosan D; Pastene DO; Sticht C; Delatorre C; van Goor H; Porubsky S; Krämer BK; Yard BA
J Mol Med (Berl); 2020 Sep; 98(9):1333-1346. PubMed ID: 32803273
[TBL] [Abstract][Full Text] [Related]
9. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
[TBL] [Abstract][Full Text] [Related]
10. Protective Actions of Anserine Under Diabetic Conditions.
Peters V; Calabrese V; Forsberg E; Volk N; Fleming T; Baelde H; Weigand T; Thiel C; Trovato A; Scuto M; Modafferi S; Schmitt CP
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30217069
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic carnosine metabolism in the human kidney.
Peters V; Klessens CQ; Baelde HJ; Singler B; Veraar KA; Zutinic A; Drozak J; Zschocke J; Schmitt CP; de Heer E
Amino Acids; 2015 Dec; 47(12):2541-50. PubMed ID: 26206726
[TBL] [Abstract][Full Text] [Related]
12. Influence of carnosine and carnosinase-1 on diabetes-induced afferent arteriole vasodilation: implications for glomerular hemodynamics.
Rodriguez-Niño A; Pastene DO; Hettler SA; Qiu J; Albrecht T; Vajpayee S; Perciaccante R; Gretz N; Bakker SJL; Krämer BK; Yard BA; van den Born J
Am J Physiol Renal Physiol; 2022 Jul; 323(1):F69-F80. PubMed ID: 35635322
[TBL] [Abstract][Full Text] [Related]
13. FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice.
Iacobini C; Menini S; Blasetti Fantauzzi C; Pesce CM; Giaccari A; Salomone E; Lapolla A; Orioli M; Aldini G; Pugliese G
Br J Pharmacol; 2018 Jan; 175(1):53-66. PubMed ID: 29053168
[TBL] [Abstract][Full Text] [Related]
14. Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency.
Peters V; Zschocke J; Schmitt CP
J Inherit Metab Dis; 2018 Jan; 41(1):39-47. PubMed ID: 29027595
[TBL] [Abstract][Full Text] [Related]
15. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1.
Janssen B; Hohenadel D; Brinkkoetter P; Peters V; Rind N; Fischer C; Rychlik I; Cerna M; Romzova M; de Heer E; Baelde H; Bakker SJ; Zirie M; Rondeau E; Mathieson P; Saleem MA; Meyer J; Köppel H; Sauerhoefer S; Bartram CR; Nawroth P; Hammes HP; Yard BA; Zschocke J; van der Woude FJ
Diabetes; 2005 Aug; 54(8):2320-7. PubMed ID: 16046297
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic insights on anserine hydrolyzing activities of human carnosinases.
Pandya VK; Shankar SS; Sonwane BP; Rajesh S; Rathore R; Kumaran S; Kulkarni MJ
Biochim Biophys Acta Gen Subj; 2023 Mar; 1867(3):130290. PubMed ID: 36529243
[TBL] [Abstract][Full Text] [Related]
17. Hydrolysis of carnosine and related compounds by mammalian carnosinases.
Pegova A; Abe H; Boldyrev A
Comp Biochem Physiol B Biochem Mol Biol; 2000 Dec; 127(4):443-6. PubMed ID: 11281261
[TBL] [Abstract][Full Text] [Related]
18. Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans.
Everaert I; Taes Y; De Heer E; Baelde H; Zutinic A; Yard B; Sauerhöfer S; Vanhee L; Delanghe J; Aldini G; Derave W
Am J Physiol Renal Physiol; 2012 Jun; 302(12):F1537-44. PubMed ID: 22496410
[TBL] [Abstract][Full Text] [Related]
19. [Carnosine, carnosinase and kidney diseases].
Kiliś-Pstrusińska K
Postepy Hig Med Dosw (Online); 2012 Apr; 66():215-21. PubMed ID: 22706107
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity.
Qiu J; Hauske SJ; Zhang S; Rodriguez-Niño A; Albrecht T; Pastene DO; van den Born J; van Goor H; Ruf S; Kohlmann M; Teufel M; Krämer BK; Hammes HP; Peters V; Yard BA; Kannt A
Amino Acids; 2019 Jan; 51(1):7-16. PubMed ID: 29922921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
